Specifica

Executive Summary

Specifica is a privately held biotechnology company founded in 2015 and headquartered in Santa Fe, New Mexico. The company specializes in antibody discovery and optimization, leveraging proprietary antibody libraries and an integrated discovery platform to generate highly diverse, high-affinity, and developable antibody candidates. By offering both services and platform transfers, Specifica aims to accelerate and de-risk the early-stage antibody development process for its partners. The company's platform is designed to address the challenges of traditional antibody discovery, including limited diversity and poor developability, by utilizing advanced library design and high-throughput screening capabilities. Since its founding, Specifica has focused on building a robust service business and establishing partnerships with biopharmaceutical companies. While the company has not disclosed total funding or valuation, its presence in the antibody discovery space positions it as a potential player in the growing market for therapeutic antibodies. Specifica's success depends on its ability to secure partnerships, deliver on its technology platform, and differentiate itself from competitors. The company is likely to remain private in the near term, with potential catalysts including new partnership announcements, platform enhancements, and expansion into new therapeutic areas.

Upcoming Catalysts (preview)

• Q2 2026New partnership with a mid-to-large pharma company40% success
• Q4 2026Launch of next-generation antibody library platform30% success
• Q3 2026Series A or B funding round announcement35% success